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The human immunodeficiency virus (HIV) type-1 viral protein U (Vpu) protein enhances the release of diverse
retroviruses from human, but not monkey, cells and is thought to do so by ablating a dominant restriction to particle
release. Here, we determined how Vpu expression affects the subcellular distribution of HIV-1 and murine leukemia
virus (MLV) Gag proteins in human cells where Vpu is, or is not, required for efficient particle release. In HeLa cells,
where Vpu enhances HIV-1 and MLV release approximately 10-fold, concentrations of HIV-1 Gag and MLV Gag fused to
cyan fluorescent protein (CFP) were initially detected at the plasma membrane, but then accumulated over time in
early and late endosomes. Endosomal accumulation of Gag-CFP was prevented by Vpu expression and, importantly,
inhibition of plasma membrane to early endosome transport by dominant negative mutants of Rab5a, dynamin, and
EPS-15. Additionally, accumulation of both HIV and MLV Gag in endosomes required a functional late-budding domain.
In human HOS cells, where HIV-1 and MLV release was efficient even in the absence of Vpu, Gag proteins were localized
predominantly at the plasma membrane, irrespective of Vpu expression or manipulation of endocytic transport. While
these data indicated that Vpu inhibits nascent virion endocytosis, Vpu did not affect transferrin endocytosis. Moreover,
inhibition of endocytosis did not restore Vpu-defective HIV-1 release in HeLa cells, but instead resulted in accumulation
of mature virions that could be released from the cell surface by protease treatment. Thus, these findings suggest that
a specific activity that is present in HeLa cells, but not in HOS cells, and is counteracted by Vpu, traps assembled
retrovirus particles at the cell surface. This entrapment leads to subsequent endocytosis by a Rab5a- and clathrin-
dependent mechanism and intracellular sequestration of virions in endosomes.
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Introduction
Human immunodeﬁciency virus (HIV) type-1 viral protein
U (Vpu) is a small (16 kDa) membrane protein encoded by
HIV-1 [1,2] and certain simian immunodeﬁciency viruses with
which HIV-1 likely shares a common ancestor [3–7]. Vpu
appears to have two major functions in HIV-1 replication
(reviewed in [8]). First, it associates with newly synthesized
CD4 in the endoplasmic reticulum and recruits bTrCP/SCF
ubiquitin ligases to mediate its degradation by proteosomes
[9], perhaps following dislocation [10]. This is thought to
prevent CD4–Env binding in the endoplasmic reticulum
[11,12], and thereby to facilitate proper Env assembly into
virions, and perhaps prevent retention of virions at the cell
surface via CD4–Env interactions [13–15]. Second, Vpu
expression enhances HIV-1 particle release by an additional,
ill-deﬁned, Env- and CD4-independent mechanism [16–19].
Vpu-defective HIV-1 mutants replicate poorly in CD4þ T
cells and macrophages [8,17], and recent studies in macaques
have demonstrated that Vpu-defective simian–HIV strains
are attenuated in vivo [20].
Structurally, Vpu consists of two major domains: an N-
terminal transmembrane (TM) domain that anchors Vpu in
cellular membranes and appears to form a cation channel
[21,22], and a cytoplasmic tail consisting of two putative a-
helices separated by a conserved casein kinase II phosphor-
ylation site [23]. Both the cytoplasmic tail and the TM
domain are required for CD4 down-regulation [24]. Con-
versely, while truncations of the cytoplasmic tail are reported
to have little effect on the ability of Vpu to enhance virion
release, mutations that truncate the TM domain or change
blocks of conserved residues within it impede this second
function [24–26].
Early studies showed that expression of Vpu could enhance
the release of diverse retroviral particles from human cells,
irrespective of whether those retroviruses normally encode a
Vpu protein [18]. More recent studies strongly suggest that
Vpu, as well as the Vpu-like activity of HIV-2 envelope
proteins [27], acts by overcoming a novel species-speciﬁc host
restriction to HIV release [28,29]. Speciﬁcally, while efﬁcient
HIV-1 particle release from African green monkey (AGM)
COS cells exhibits no requirement for Vpu expression,
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human cell lines appears Vpu-dependent [28]. Additionally,
the Env protein of HIV-2, previously reported to harbor a
Vpu-like activity in that it stimulates virion release [27], also
enhances HIV-1 and murine leukemia virus (MLV) release
from simian–human cell heterokaryons [29]. The host factors
responsible for this apparently dominant restriction and the
method by which they act to inhibit release are undeﬁned at
present. Nonetheless, several electron microscopy studies
showed that Vpu-defective HIV-1 accumulates as morpho-
logically mature virion particles at the plasma membrane
(PM) and in intracellular vacuoles [17,18]. In addition, one
previous study suggested that Vpu changes the subcellular
localization of HIV-1 Gag [30].
The matrix domain of HIV-1 Gag is largely responsible for
targeting to the cellular membrane, but conﬂicting studies
have postulated a role for HIV-1 matrix in Vpu-mediated
particle release [31,32]. Nonetheless, the appearance of HIV-1
Vpu-defective particles in internal membrane-bound com-
partments [17,18] is suggestive of a Gag targeting defect, or a
defect in the endosome-to-PM trafﬁcking pathway that has
recently been proposed to be important for retrovirus
assembly and release [33–41]. Importantly, the HIV-1 mor-
phogenesis defect associated with Vpu deﬁciency is distinct
from that associated with p6 mutations that abolish late-
budding domain (L-domain) function [42]. In the latter case,
class E vacuolar protein-sorting (VPS) factor recruitment is
defective, resulting in maintenance of continuity between
viral and cellular membrane and accumulation of incom-
pletely formed immature virions at the PM [43,44].
In this study, we determined the effects of Vpu on HIV-1
and MLV Gag distribution in cells where Vpu is required, or
not required, for efﬁcient virion release. Notably, we ﬁnd that
Vpu can cause a dramatic change in HIV-1 and MLV Gag
localization in cells where it enhances virus release. Specif-
ically, Vpu prevented accumulation of HIV-1 and MLV Gag in
endosomal compartments. Interestingly, inhibition of endo-
cytosis or early endosome function similarly prevented the
intracellular accumulation of Gag in endosomes, but did not
rescue Vpu-defective virus release. Moreover, Gag local-
ization to endosomes required that it be competent to
complete late-budding steps. Thus, we propose that Vpu
overcomes a host activity that prevents the release of
completely formed virions from the cell surface, and that
this host cell–speciﬁc activity leads to subsequent virion
endocytosis and sequestration in endosomes.
Results
Vpu-Mediated Enhancement of Retroviral Release Is
Human Cell Type–Dependent
To permit studies of the effects of Vpu on retrovirus
assembly and release, we ﬁrst sought to identify human cell
lines in which particle release was Vpu-dependent and
-independent. Cells were transfected with an HIV-1 proviral
plasmid (NL4.3), a Vpu-defective derivative (NL4.3delVpu), or
an MLV Gag-Pol–expression plasmid along with plasmids
expressing green ﬂuorescent protein (GFP, as a control), Vpu,
or an inactive Vpu mutant in which the TM domain was
replaced by that of human CD8 (V8). As expected, Western
blot and infectious virion titration assays showed that HIV-1
release from human HeLa cells was clearly responsive to Vpu
(Figure 1). Speciﬁcally, the levels of extracellular virions, as
detected by an anti-p24CA antibody, from cells transfected
with the NL4.3delVpu proviral plasmid, were signiﬁcantly
reduced as compared to those released from wild-type
proviral plasmid-transfected cells, despite equivalent levels
of precursor p55Gag levels in the cell lysates (Figure 1A).
Expression of Vpu in trans rescued Vpu-defective HIV-1
release to levels similar to those of the wild-type virus,
whereas the mutant Vpu, V8, was inactive (Figure 1A).
As has previously been shown [18,29], Vpu also stimulated
MLV particle release from HeLa cells (Figure 1B). In the case
of MLV, it was notable that more mature processed capsid
(CA, p30) accumulated in HeLa cells in the absence of Vpu
than in its presence, despite unchanged levels of Pr65 Gag
precursor (Figure 1B). Thus, Vpu expression apparently
reduced HeLa cell–associated mature MLV CA and redis-
tributed it to the culture supernatant. Infectious virion–
release assays also showed that Vpu expression enhanced
NL4.3delVpu release from HeLa cells by approximately 10-
fold, as assayed by b-galactosidase activity in TZM indicator
target cells (Figure 1C). A similar increase in yield of
infectious MLV vector particles (pseudotyped with VSV-G
and carrying an HIV-1 Tat–expressing vector) was obtained
in response to Vpu expression in virus-producing HeLa cells
(Figure 1D).
In contrast, the effect of Vpu on HIV-1 or MLV release was
very different in HOS cells (Figure 1A–1D). Speciﬁcally,
NL4.3 and NL4.3delVpu were released equivalently from
HOS cells, and there was no discernable effect of Vpu
expression in trans on the level of HIV-1 or MLV particle
release, measured using Western blot or infectious particle
assays (Figure 1A–1D). Curiously, when compared to HeLa
cells, HOS cell lysates appeared to contain proportionally less
HIV-1 CA compared to p55Gag (Figure 1A). Moreover, only
low levels of mature or immature MLV Gag were detected in
HOS cell lysates, despite reasonably abundant particle yield
from culture supernatants (Figure 1B). These data suggested
that mature HIV-1 and MLV particle release is somewhat
more efﬁcient from HOS cells than from HeLa cells. Finally,
as a control, AGM Vero cells were also tested, and these
results were consistent with previous studies that HIV-1
release from AGM cells is unresponsive to Vpu expression
[28] (Figure 1A–1D). Taken together, these results show that
the ability of Vpu to enhance retroviral release is not only
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Synopsis
Human immunodeficiency virus (HIV) type-1 encodes a small
protein, termed HIV-1 viral protein U (Vpu), which enhances the
release of retroviral particles from certain cell types. This study
shows that Vpu affects the distribution of the major retroviral
structural protein within cells. In particular, the viral structural
protein was initially detected at the exterior surface of the cell,
where it assembles into particles, but over time was internalized.
Vpu prevented internalization, and instead induced the release of
particles from the cell surface. The effect of Vpu was specific for
retroviral particles and simply blocking particle internalization did
not obviate the requirement for Vpu. These experiments strongly
suggest that Vpu counteracts a cellular activity that traps newly
formed retrovirus particles at the cell surface. Surface entrapment of
retroviral particles ultimately leads to their internalization to the cell
interior, rather than their release to infect new cells.dependent on host-cell species, as previously shown [28], but
is also human cell type–dependent.
HIV-1 and MLV Gag Accumulate in Endosomal
Compartments in HeLa Cells but Not in HOS Cells, and
This Accumulation Is Prevented by Vpu
Having identiﬁed human cell types (HeLa and HOS) in
which Vpu expression differentially affected retroviral
particle release, we next examined whether HIV-1 and MLV
Gag proteins displayed any differences in distribution in
HeLa and HOS cells. Cells were transfected with plasmids
expressing HIV-1 or MLV Gag-CFP, then ﬁxed and observed
by deconvolution microscopy. Initially, observation was done
using cells ﬁxed at 18 h after transfection, and we found that
HIV-1 and MLV Gag-CFP could exhibit three distinct
patterns of localization in HeLa cells. First, a diffuse
cytoplasmic ﬂuorescence was observed primarily in cells
expressing apparently lower levels of Gag-CFP (unpublished
data). Alternatively, in cells expressing apparently higher
levels of Gag-CFP, the ﬂuorescent signal could be observed to
be concentrated primarily either at the PM or in intracellular
accumulations. Mixed distributions could also be observed
and examples are shown in Figure 2A. In contrast, Gag-CFP
only rarely exhibited discrete intracellular accumulations in
HOS cells, with most cells exhibiting only PM-associated
accumulation or low-level diffuse ﬂuorescence (Figure 2B). By
simply counting the number of Gag-CFP–positive cells on the
basis of whether CFP accumulated only at the PM or at both
the PM and intracellular compartments, we found that for
both HIV-1 and MLV Gag-CFP, the majority of HeLa cells
(;70%) exhibited clear intracellular accumulations of Gag-
CFP, as well as PM ﬂuorescence (Figure 2C), while less than
5% of HOS cells exhibited intracellular accumulations of
Gag-CFP.
Notably, expression of Vpu along with Gag-CFP in HeLa
cells dramatically reduced the number of cells containing
intracellular Gag-CFP accumulations. This result was ob-
tained with both HIV-1 Gag-CFP and MLV Gag-CFP (Figure
2C and 2D). In marked contrast, Vpu had no effect on HIV-1
or MLV Gag-CFP localization in HOS cells (Figure 2C;
Figure 1. Cell Type–Dependent Effects of Vpu on Retroviral Particle Release
Human HeLa and HOS cells, together with AGM Vero cells, were transfected with HIV-1 NL4.3 and NL4.3delVpu proviral plasmids, or an MLV Gag-Pol–
expression vector, as indicated, in the presence of plasmids expressing either no Vpu (none), codon-optimized Vpu, or an inactive Vpu mutant
containing a CD8 TM domain (V8).
(A and B) Western blot analyses of cell and virion lysates, probed using antibodies to HIV-1 (A) or MLV CA (B).
(C and D) Results of chemiluminsecent b-galactosidase assays following inoculation of HeLa-TZM indicator cells with supernatants derived from HeLa,
HOS, or Vero cells transfected with NL4.3 (white bars) or NL4.3delVpu (black bars) proviral plasmids (C) or plasmids expressing MLV Gag-Pol, a
packageable HIV-1 Tat–expression vector, and VSV-G (D). Vpu and control (GFP)–expression plasmids were included, as indicated, and results plotteda s
relative light units (RLU) 6 standard deviation of the mean.
DOI: 10.1371/journal.ppat.0020039.g001
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Vpu and Retrovirus Releaseunpublished data). Importantly, the inactive mutant Vpu, V8,
failed to prevent the occurrence of intracellular concen-
trations of HIV-1 Gag-CFP in HeLa cells (Figure 2E and 2F).
Thus, the Vpu TM domain that is critical for virus release
function [24] (Figure 1), is also required for effecting changes
in HIV-1 and MLV Gag localization (Figure 2E and 2F),
speciﬁcally in cells (HeLa) where Vpu is required for efﬁcient
virion release.
Intracellular accumulations of HIV-1 and MLV Gag have
been proposed to be a consequence of Gag targeting and/or
virion budding into late endosomal compartments [33–40].
Consistent with this, and as has been previously reported
[34,36,37], some of the intracellular accumulations of HIV-1
Gag-CFP in HeLa cells were coincident with late endosomes as
revealed by antibody staining for CD63 (Figure 3A). However,
co-expression of HIV-1 Gag-CFP with a cherry ﬂuorescent
protein (CherryFP)–Rab5a fusion protein also revealed some
degree of co-localization (Figure 3B). Rab5a is a GTPase that is
responsible for regulating endocytic vesicle trafﬁcking from
the PM and the formation of early endosomes [45]. Thus, this
result indicated that a proportion of HIV-1 Gag-CFP localizes
to early endosomes (Figure 3B). In some cases, the Gag-CFP
signal appeared to be surrounded by a CherryFP-Rab5a signal
(Figure 3B, lower panels). A similar degree of co-localization
Figure 2. Expression of Vpu Prevents Intracellular Accumulation of Retroviral Gag-CFP Fusion Proteins in HeLa Cells
Cells were transfected with the indicated expression vectors, fixed 18 h after transfection, and observed by deconvolution microscopy.
(A and B) Localization of HIV-1 Gag-CFP or MLV Gag-CFP in HeLa cells (A) or HOS cells (B) in the absence of Vpu. Two examples of each cell type and
each Gag-CFP protein are shown. White bars in the micrographs indicate a distance of 10 lm.
(C) Quantitative analysis of these effects. Ten random fields of HeLa and HOS cells expressing HIV-1 or MLV Gag-CFP proteins in the presence or absence
of Vpu were inspected, and the numbers of cells in which Gag-CFP was observed as accumulations at the PM only (black bars), at intracellular sites as
well as at the PM (white bars), or as diffuse cytoplasmic fluorescence only (grey bars) were counted. Enumeration of cells with each pattern of Gag-CFP
localization is expressed as a percentage the total of the cells counted, which was 75 6 7 for each condition and is a representative example of three
separate experiments.
(D) Examples of HeLa cells expressing HIV-1 Gag-CFP (upper panels) or MLV Gag CFP (lower panels) in the presence of co-expressed Vpu.
(E and F) The Vpu TM domain is required to prevent intracellular accumulation of HIV-1 Gag-CFP. (E) Examples of HeLa cells expressing HIV-1 Gag-CFP
and V8. White bars in the micrographs indicate a distance of 10 lm. (F) Cells expressing HIV-1 Gag-CFP only, Gag-CFP and Vpu, or Gag-CFP and V8 were
inspected and enumerated as described in (C), except that cells containing only diffuse Gag-CFP and no visible accumulations were excluded from the
analysis.
DOI: 10.1371/journal.ppat.0020039.g002
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Vpu and Retrovirus Releasewith each of these endosomal markers was also observed with
MLV Gag-CFP (unpublished data).
Based on this result, we hypothesized that Vpu might affect
retroviral Gag trafﬁcking through endosomes en route to the
PM. In other words, in cells that require Vpu for efﬁcient
particle release, Gag molecules might be inappropriately
targeted to endosomal compartments or retarded during
transit through endosomal compartments. The likely con-
sequence of such a scenario would be a failure or a delay in
accumulation of Gag at the PM. To examine the kinetics of
Gag accumulation at intracellular versus PM sites, we ﬁxed
HeLa cells at various times after transfection with an HIV-1
Gag-CFP–expression plasmid and counted the number of
transfected cells that exhibited diffuse, PM, or internal Gag
accumulations (Figure 4A). Surprisingly, visible accumulation
of Gag-CFP at the PM signiﬁcantly preceded visible accumu-
lation at intracellular sites. Indeed, at early time points (,12
h after transfection) cells exhibiting Gag-CFP accumulations
exclusively at the PM predominated and increased over time.
However, at later time points (.12 h after transfection), the
fraction of cells with signiﬁcant intracellular Gag-CFP
Figure 3. Intracellular HIV-1 Gag-CFP Partly Co-localizes with both Early
and Late Endosomal Markers in HeLa Cells
(A) HeLa cells expressing HIV-1 Gag-CFP (green) were fixed 18 h post-
transfection and stained with a monoclonal antibody specific for human
CD63, and a secondary anti-mouse Alexa-Fluor-588 conjugate (red).
Nuclei were counter-stained with DAPI (blue).
(B) HeLa cells expressing HIV-1 Gag-CFP (green) were co-transfected with
CherryFP-Rab5a (red), a marker for early endosomal structures. Cells were
fixed and images acquired at 18 h post-transfection. The lower set of
images presented in (B) are shown at approximately 5-fold higher
magnification to give a clearer indication of the juxtaposition of the HIV-
1 Gag-CFP and CherryFP-Rab5a signals. White bars in the micrographs
indicate a distance of 10 lm, except in the lower set of images in (B),
where the bar indicates 2 lm
DOI: 10.1371/journal.ppat.0020039.g003
Figure 4. HIV-1 Gag-CFP Accumulation at the PM Precedes Accumu-
lation at Intracellular Sites in HeLa Cells in the Absence of Vpu Expression
(A and B) HeLa cells were transfected with HIV-1 Gag-CFP and either an
irrelevant plasmid control (A) or a Vpu-expression plasmid (B). The cells
were washed 5 h post-transfection and then fixed at 2-h intervals
thereafter. The number of cells in ten fields that exhibited HIV-1 Gag-CFP
accumulations at the PM only or at the PM and intracellular sites, or
which expressed only diffuse Gag-CFP, were enumerated as in Figure 1C
and plotted as the percentage of the total. Cells containing only diffuse
Gag-CFP have been omitted from the charts for simplicity.
DOI: 10.1371/journal.ppat.0020039.g004
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Vpu and Retrovirus Releaseaccumulations, in addition to PM ﬂuorescence, increased
(Figure 4A). Indeed, these cells eventually predominated and,
by 16–18 h after transfection, an apparent steady state was
achieved, with approximately 70% of the transfected cells
containing primarily intracellular Gag-CFP accumulations. In
marked contrast, co-expression of Vpu with Gag-CFP
prevented the accrual of cells containing intracellular Gag-
CFP accumulations, and cells exhibiting PM ﬂuorescence
exclusively increased over time to represent 60–70% of the
total number of transfected cells (Figure 4B). Under this
condition, the number of cells containing intracellular Gag-
CFP accumulations always remained low (,12% of the total).
Endosomal Gag-CFP and Virion Accumulation in HeLa
Cells Is Prevented by Inhibiting Endocytosis or Early
Endosome Function
These results suggested that HIV-1 Gag-CFP accumulates
ﬁrst at the PM of HeLa cells and, in the absence of Vpu,
subsequently accumulates in endosomes. Conversely, Vpu
expression prevented endosomal localization and preserved
the early, primarily PM, distribution of HIV-1 Gag-CFP. This
result indicated that Vpu is not required for PM targeting of
Gag and suggested the possibility that intracellular accumu-
lations of Gag-CFP might arise via endocytosis of Gag
molecules or nascent virion particles that are retained on
the PM of HeLa cells in the absence of Vpu. To test this idea,
HeLa cells were co-transfected with plasmids expressing HIV-
1 Gag-CFP in the presence of dominant inhibitors of
endocytosis. Thereafter, cells were examined at 18 h after
transfection, at which time intracellular Gag-CFP accumu-
lations would predominate (Figures 2–4). Remarkably, ma-
nipulation of PM to early endosome transport pathways
dramatically affected HIV-1 Gag-CFP localization in HeLa
cells, but not in HOS cells (Figure 5A–5C). Speciﬁcally,
expression of dominant negative (DN) forms of dynamin
(K44A) and EPS-15 (YFP-DN EPS-15), both of which are
known to inhibit clathrin-mediated endocytosis [46], signiﬁ-
cantly reduced the accumulation of Gag-CFP at intracellular
sites in HeLa cells (Figure 5A and 5C). Furthermore,
expression of CherryFP-Rab5a(S34N), a mutant of Rab5a
that fails to bind GTP, blocks endocytic vesicle fusion and
Figure 5. DN Mutants of Cellular Proteins that Mediate PM-to-Early-
Endosome Transport Affect Gag-CFP Localization in HeLa, but Not HOS
Cells
(A) HeLa cells (left panels) or HOS cells (right panels) were transfected
with plasmids expressing HIV-1 Gag-CFP (green) and either dynamin
K44A (no color) or dnEPS-15-YFP (red). Cells were fixed at 18 h post-
transfection and analyzed using deconvolution microscopy.
(B) HeLa cells (upper and center panels) expressing HIV-1 Gag-CFP
(green), and either DN (S34N) or constitutively active (Q79L) mutants of
CherryFP-Rab5a (red), were fixed and images acquired 18 h post-
transfection. The far-right-center panel shows an example of how
localization of HIV-1 Gag-CFP in swollen CherryRab5aQ79L early endo-
somes could be resolved as apparently particulate fluorescence within a
vesicle lumen. (B, lower panels) shows a similar analysis HIV-1 Gag-CFP
localization (green) in the presence of CherryFP-Rab5a(Q79L) in HOS
cells. White bars in the micrographs indicate a distance of 10 lm, except
in the far-right-center panel of (B) where a distance of 1 lm is indicated.
(C) The numbers of HIV-1 Gag-CFP–expressing cells in ten fields
exhibiting PM Gag-CFP accumulation only (black bars) or additional
intracellular accumulations (white bars) in the presence of the indicated
co-expressed cellular proteins was counted, as in Figure 2C, and is
plotted as a percentage of the total number of cells with Gag-CFP
accumulations.
DOI: 10.1371/journal.ppat.0020039.g005
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Vpu and Retrovirus Releaseinhibits the uptake of both ﬂuid-phase and receptor-
mediated endocytic cargo [47–49], and almost completely
abolished the appearance of intracellular HIV-1 Gag-CFP in
HeLa cells (Figure 5B and 5C). This effect was not observed
upon co-expression of Gag-CFP with the wild-type Rab5a
protein (Figures 3B and 5C).
Interestingly, expression of a ‘‘constitutively active’’ form
of Rab5a(Q79L), which binds GTP but cannot hydrolyze it
[47], and which leads to the generation of a swollen early
endosomal compartment, also affected Gag-CFP localization
(Figure 5B). However, in this case, while the proportion of
HeLa cells that exhibited intracellular HIV-1 Gag-CFP
accumulation remained similar (Figure 5C), the vast majority
of intracellular HIV-1 Gag-CFP co-localized with CherryFP-
Rab5a(Q79L) (Figure 5B). This result indicates that Ra-
b5a(Q79L) can trap HIV-1 Gag-CFP in an aberrant early
endosome compartment, and presumably prevent further
transit to CD63þ late endosomes (Figure 3B). In some cases,
these swollen endosomes could be resolved as Rab5a-bound
structures containing distinct Gag-CFP accumulations (Fig-
ure 5B, far-right panel). Importantly, the wild-type form of
Rab5a had no effect on the localization of Gag-CFP in HeLa
cells (Figure 3), and neither wild-type nor mutant Rab5a
proteins had any effect on Gag-CFP localization in HOS cells.
Indeed, Gag-CFP accumulations in HOS cells remained
robustly at the PM despite any of the aforementioned
manipulations of endocytosis (Figure 5A–5C). Thus, the effect
of Vpu expression on HIV-1 Gag localization in HeLa cells
can be recapitulated by factors that inhibit endocytosis, and
this suggests that Vpu blocks a cellular activity that ultimately
results in the endocytosis of Gag molecules or virions.
To verify that the aforementioned effects were not an
artifact of the use of Gag-GFP fusion proteins, we repeated
several experiments using full-length or Vpu-defective HIV-1
proviral plasmids, coupled with Gag detection by immuno-
ﬂuorescence. As can be seen in Figure 6A, immunoﬂuor-
escent detection of Gag revealed that it accumulated
primarily at the PM of HeLa cells when expressed in the
context of an intact proviral plasmid, but was also observed in
intracellular compartments when a Vpu-defective proviral
plasmid was used. Conversely, Gag accumulations were
exclusively at the PM of HOS cells, even when expressed in
Figure 6. Immunofluorescent Localization of HIV-1 Gag Expressed from a
Proviral Construct and Effects of Vpu and Endocytosis Inhibitors
(A) HeLa cells (left and center panels) or HOS cells (right panel) were
transfected with NL4.3 or NL4.3delVpu proviral plasmids, as indicated.
Gag localization was determined by immunofluorescence using an a-CA
antibody as described in Materials and Methods.
(B) HeLa cells expressing Gag from the NL4.3delVpu proviral plasmid, and
either DN (S34N, upper panels) or constitutively active (Q79L center and
lower panels) mutants of CherryFP-Rab5a (red), were fixed and subjected
to immunofluorescence to detect HIV-1 Gag (green) at 20 h post-
transfection. White bars in the micrographs indicate a distance of 10 lm.
The lower three images in (B) show expanded views of a portion of the
overlay panels (indicated by the dashed squares) to exemplify how HIV-1
Gag and the CherryRab5a proteins are juxtaposed, Note that Gag
sometimes appears to be within the lumen of the CherryFP-
Rab5a(Q79L)–marked endosomes.
(C) The numbers of HIV-1 Gag–expressing cells in ten fields exhibiting PM
Gag immunofluorescence only (black bars) or additional intracellular
accumulations (white bars) after transfection with NL4.3 or NL4.3delVpu
proviral plasmids in the presence of the indicated co-expressed cellular
proteins was counted, as in Figure 2C. Data are plotted as a percentage
of the total number of cells with visible Gag accumulations.
DOI: 10.1371/journal.ppat.0020039.g006
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prevented detectable intracellular accumulation of intra-
cellular Gag in HeLa cells, while Rab5a(Q79L) showed
signiﬁcant co-localization with Gag (Figure 6B). Indeed,
authentic HIV-1 Gag often appeared to be contained within
Rab5a(Q79L)–bound aberrant endosomes (Figure 6B, lower
panels). Enumeration of cells exhibiting PM only, or of cells
exhibiting additional intracellular accumulations, revealed
that authentic Gag molecules behaved in essentially the same
way as Gag-GFP in terms of the effects of Vpu and inhibitors
of endocytosis.
In addition, electron microscopy examination of HeLa cells
expressing HIV-1 Gag-Pol revealed accumulations of virus
particles at both the PM and in intracellular compartments
that were apparently membrane-bound (Figure 7A–7C). The
majority of these particles had condensed cores, indicating
that they were mature, and this was consistent with previous
reports that characterized Vpu-defective viruses in T cells
[17,18]. Co-expression of Vpu resulted in fewer cell-associ-
ated particles (Figure 7D), with no particles detected in
intracellular compartments. Similarly, no intracellular par-
ticles were observed in cells co-expressing Gag-Pol and
Rab5a(S34N), but numerous extracellular particles contain-
ing apparently condensed cores were observed. Many of these
appeared close to or associated with the extracellular surface
of the PM (Figure 7E and 7F).
Inhibition of Endocytosis Does Not Induce Vpu-
Independent HIV-1 Release
Because inhibition of endocytosis recapitulated the effect
of Vpu on Gag localization (Figures 5 and 6), we next asked
whether Vpu facilitated virion release from HeLa cells simply
by inducing an arrest of endocytosis. Fluorescently labeled
Alexa-Fluor-568 transferrin (red) was used as a traceable
endocytic cargo and, as can be seen in Figure 7, HeLa cells
that were marked by transfection with a GFP-expression
Figure 7. Electron Microscopy Examination of HIV-1 Assembly and Effects of Vpu and Endocytosis Inhibition
Hela cells expressing Gag-Pol in the presence or absence of Vpu or Rab5a(S34N) were examined.
(A–C) Examples of cells expressing Gag-Pol only, revealing mature particles at both the PM (A and C) and within internal, apparently membrane-bound
compartments (arrows in A and B). Immature budding structure are also observed at the PM but only rarely within endosomes.
(D) Cells co-expressing Gag-Pol and Vpu with reduced numbers of cell-associated particles, and absence of particles from endosomes.
(E and F) Cells co-expressing Gag-Pol and Rab5a(S34N), with exclusively surface-accumulated virions.
DOI: 10.1371/journal.ppat.0020039.g007
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Vpu and Retrovirus Releaseplasmid efﬁciently internalized transferrin (Figure 8). Con-
versely, co-expression of dynamin K44A (as a control) with
GFP abolished detectable transferrin uptake by HeLa cells or
by HOS cells, and labeled transferrin remained at the PM of
GFP-positive cells (Figure 8; unpublished data). Notably, GFP
and Vpu co-expression did not affect transferrin uptake in
either HeLa (Figure 8) or HOS cells (unpublished data),
indicating that Vpu does not induce a general block in
clathrin-dependent endocytosis.
Next, we transfected HeLa and HOS cells with NL4.3 or
NL4.3delVpu proviral plasmids along with plasmids express-
ing either Vpu, dynamin K44A, DN EPS-15, or Rab5a
mutants. As can be seen in Figure 9, expression of Vpu in
trans speciﬁcally enhanced the release of NL4.3delVpu
(Figure 9A and 9B), but none of the aforementioned
dominant inhibitors of endocytosis, which prevented intra-
cellular accumulation of Gag and/or particles (Figures 4–6),
could recapitulate this activity. Together these results
demonstrate that generalized inhibition of endocytosis per
se does not explain how Vpu stimulates retrovirus particle
release. Moreover, inhibition of endocytosis did not appear to
affect Vpu activity since NL4.3 was released more efﬁciently
than NL4.3delVpu, even in the presence of each of the
endocytosis inhibitors.
Endosomal Accumulation of Retroviral Gag Proteins in
HeLa Cells Requires a Functional L-Domain
Retroviral Gag proteins encode small peptide motifs (L-
domains) that recruit components of the class E VPS
machinery that are required for nascent virion generation
via the ﬁssion of virion and cellular membranes (reviewed in
[43,44]). The block imposed on virion release by L-domain
mutation results in the accumulation of nearly complete, but
immature, membrane-tethered virions, as opposed to the
apparently mature virions that accumulate in the absence of
Vpu (Figure 7). Thus, given that intracellular, Vpu-defective
virions appear to arise via endocytosis, the block to virion
release imposed by the Vpu defect seems to occur sub-
sequently to that imposed by an L-domain defect. Therefore,
we next asked whether a functional L-domain and, by
inference, either recruitment of class E VPS factors or
separation of virion and cell membranes, was required for
endocytosis of Gag or nascent virions by HeLa cells.
Interestingly, while wild-type HIV-1 Gag-CFP localized to
internal structures in HeLa cells, as before, a mutant
containing inactivating mutations in both the TSG101-bind-
ing PTAP motif [50–52] and the AIP1/ALIX–binding LrsLF
motif [53] accumulated exclusively at the PM, even in the
absence of Vpu (Figure 10). This observation is consistent
with a previous study which showed that the HIV-1 PTAP
motif is required for detection of HIV-1 Gag in a biochemi-
cally enriched fraction containing endosomes [39].
Interestingly, we also found that a mutant MLV Gag-CFP
protein (MLV GagdPY-CFP) that lacks the PPPY motif
required for the binding of HECT ubiquitin ligases [54]
failed to accumulate at intracellular locations (Figure 10B and
10C), unlike the wild-type MLV Gag-CFP protein. Conversely,
a mutant MLV Gag-CFP protein, in which the PPPY L-
domain was replaced by the PTAP motif from HIV-1, behaved
like wild-type MLV Gag-CFP and localized to internal
structures in the absence of Vpu, but was exclusively PM-
associated when Vpu was co-expressed (unpublished data).
Figure 8. Vpu Expression Has No Effect on Transferrin Endocytosis
HeLa cells were transfected with a control plasmid, or with plasmids
expressing dynamin K44A, or Vpu together with a GFP-expression
plasmid to mark transfected cells. Five hours after transfection, cells were
transferred to serum-free medium. After overnight incubation, cells were
then washed and incubated in fresh medium containing 5 lg/ml of
transferrin conjugated to Alexa-Fluor-568. After 15 min of incubation,
cells were fixed and images acquired.
DOI: 10.1371/journal.ppat.0020039.g008
Figure 9. Inhibition of Endocytosis or Early Endosome Function Does Not
Restore Vpu-Deficient HIV-1 Release
HeLa cells were transfected with NL4.3 (A) or NL4.3delVpu (B) proviral
plasmids along with plasmids expressing GFP or Vpu (as controls),
dynamin K44A, DN EPS-15, or wild-type and mutant Rab5a proteins. Cell
and virus lysates were harvested 48 h post-transfection, and analyzed by
Western blotting with an HIV-1 CA-specific monoclonal antibody
DOI: 10.1371/journal.ppat.0020039.g009
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Gag contains functional L-domain sequences, and either
PTAP or PPPY motifs can mediate this effect. This ﬁnding
suggests that the endocytosis of nascent virions that can occur
in the absence of Vpu requires that virion and cell
membranes should be discontinuous, or that L-domains
recruit factors required for Gag or virion endocytosis.
Mature, Vpu-Defective Virion Particles Are Tethered to the
Surface of HeLa Cells by Protease-Sensitive Factor(s)
Since the aforementioned experiments (Figures 7 and 10)
suggested that the Vpu defect imposes a block to virion
release that is subsequent to the action of L-domains, we
reasoned that particle endocytosis was likely a downstream
consequence of the failed release of fully formed virions from
the PM. Implicit in this scenario is some form of post-
budding adhesion of nascent virions to the surface of the
HeLa cells from which they are derived. To test this notion,
HeLa cells were transfected with NL4.3 or NL4.3delVpu
proviral plasmids, and the level of particles that were either
constitutively released, or were released only following
treatment with a protease (subtilisin) was determined (Figure
11). As expected, NL4.3 virions were constitutively released
more efﬁciently than NL4.3delVpu virions. Indeed, far fewer
NL4.3 virions remained associated with HeLa cells (in a form
that could be released by subtilisin treatment), than the
number that were constitutively released (Figure 11A).
In contrast, a signiﬁcant proportion (at least half) of the
virions generated by NL4.3delVpu-transfected HeLa cells
were not constitutively released, but could be released
following subtilisin treatment (Figure 11B). Thus, the absence
of Vpu resulted in a loss of extracellular virion production in
favor of an increase in a mature virion population, containing
fully processed CA, which could be released from cells by
subtilisin. The number of Vpu-defective virions that were
released from HeLa cells by susbtilisin treatment was
increased when cells co-expressed Rab5a(S34N) to inhibit
endocytosis (Figure 11B). Indeed, in this case, the quantity of
virions that were released by subtilisin signiﬁcantly exceeded
the quantity that were constitutively released, and actually
approached the levels that were constitutively released by the
Vpu-competent provirus-transfected cells (Figure 11A and
11B). Notably, subtilisin induced the release of particles that
predominantly contained fully processed p24CA and very
little p55Gag precursor, suggesting that the particles that were
released by protease treatment were fully mature virions.
As a control, the effect of subtilisin on the release of HIV-1
virions lacking a functional L-domain NL4.3 (PTAP
 ) was
determined (Figure 11C). In the case of this L-domain
mutant, virions are known to remain immature and accumu-
late at the PM, tethered by a membrane that is contiguous
with that of the host cell. Importantly, subtilisin treatment
did not increase the release of NL4.3 (PTAP
 )v i r o n s ,
irrespective of Rab5(S34N) co-expression. This ﬁnding
indicates that subtilisin treatment does not compromise the
integrity of the PM and that Vpu-defective virions differ from
late-budding domain mutant virions in that the former are
tethered to the PM by one or more protease-sensitive
factor(s), and not by continuity between the virion envelope
and the PM.
Discussion
Although Vpu can strongly induce retrovirus particle
release from cells, we, and others, have not observed co-
localization, or any other form of interaction, between
retroviral Gag proteins and Vpu (unpublished data). Vpu
can localize to intracellular membranes of the endoplasmic
reticulum, golgi, and endosomal structures, as well as the PM
[17,55,56]. While ER localization is required for CD4 down-
regulation, and may be required for enhancement of virus
release [57], the site at which events relevant to particle
release occur is not unambiguously established. A recent
study that showed that expression of DN Rab11a or MyosinVb
can inhibit HIV-1 release in the presence of Vpu suggests that
a functioning recycling endosomal compartment is required
[56]. Since Vpu localizes to sites distinct from those at which
retroviral particles assemble, and from which they are
released, it seems likely that the virus-release function of
Vpu results from indirect effects on the host cell, rather than
on speciﬁc components of the virion. Our ﬁndings are
Figure 10. Endosomal Accumulation of HIV-1 and MLV Gag-CFP Requires
a Functional L-Domain
HeLa cells were transfected with plasmids expressing HIV-1 (A) or MLV
Gag-CFP (B), or mutant variants thereof lacking functional L-domains
(HIV-1 Gag dLD-CFP and MLV Gag dPY-CFP, respectively) in the presence
or absence of co-expressed Vpu, as indicated. The cells were fixed at 18 h
post-transfection and images acquired. Representative examples are
shown in panels (A) and (B) and a quantitative assessment of Gag-CFP
localization, enumerated as in Figure 1, is shown (C). The numbers of
HIV-1 Gag-CFP–expressing cells in ten fields exhibiting Gag-CFP
accumulation only at the PM (black bars) or at intracellular sites (white
bars) were counted, as in Figure 2C, and are plotted as a percentage of
the total number of cells with Gag-CFP accumulations.
DOI: 10.1371/journal.ppat.0020039.g010
PLoS Pathogens | www.plospathogens.org May 2006 | Volume 2 | Issue 5 | e39 0363
Vpu and Retrovirus Releaseconsistent with this notion, particularly when viewed along-
side a recent study that strongly suggested that Vpu over-
comes a host cell–speciﬁc restriction to retrovirus particle
release in human cells [28].
The effect of Vpu on virus release varied signiﬁcantly
among human cell lines, and HeLa cells proved particularly
useful for studying this property, because Vpu stimulated
both HIV-1 and MLV release by about 10- to 20-fold from
these cells [18]. Conversely, human HOS cells served as a
useful control, because efﬁcient HIV-1 and MLV release was
completely independent of Vpu, as was previously shown to
be the case in AGM cells [28]. By observing the localization of
Gag-CFP fusion proteins as well as authentic Gag proteins in
HeLa and HOS cells, we found that Vpu prevented the
accumulation of HIV-1 and MLV Gag in HeLa cell endosomal
compartments, and instead constrained Gag accumulation to
the PM. In the absence of Vpu, accumulation of Gag at
intracellular sites required a functional L-domain and was
blocked by inhibitors of clathrin-dependent endocytosis (DN
dynamin and EPS-15) or the function of early endosomes (DN
Rab5a). Our observations strongly suggest that accumulations
of retroviral Gag proteins and virion particles in endosomes,
observed here and previously in the context of defective Vpu
[17,18,30], arise from endocytosis of completely assembled
virions from the PM. Consistent with this notion, an aberrant
early endosomal compartment that is induced and marked by
Rab5a(Q79L) appeared to contain the majority of intra-
cellular HIV-1 Gag in the absence of Vpu.
It is important to note that while these experiments
document a PM-to-endosome trafﬁcking route for two
retroviral Gag proteins, they do not address how Gag ﬁrst
achieves PM localization. Indeed, several groups have
suggested that retroviral Gag molecules and/or completely
assembled particles trafﬁc to the PM and/or leave the cell via
an intermediate step that involves Gag localization and even
particle formation in endosomes [33–40]. While the existence
of a late endosome-to-PM trafﬁcking route for HIV-1
particles or assembly intermediates has gained wide accept-
ance [58], the precise method by which Gag moves to the PM
in non-macrophage cell types remains somewhat ambiguous.
The ﬁndings reported herein highlight the need to distin-
guish between Gag molecules that are directly targeted to
endosomal membranes and those that arrive in endosomes as
a consequence of virion endocytosis from the PM. Given the
dramatic effects of the host-cell type, the presence or absence
of Vpu, and the effect of Gag expression level on steady-state
Gag distribution [59,60], it is perhaps unsurprising that there
is wide discordance among studies that have determined this
superﬁcially simple parameter.
While Vpu appeared to prevent endocytosis of nascent
retrovirus particles, it did not appear to inhibit endocytosis
in a general sense, as judged by transferrin-uptake assays.
Moreover, generalized inhibition of endocytosis prevented
intracellular accumulation of HIV-1 and MLV Gag but could
not substitute for Vpu function. Therefore, we propose that
endocytosis of nascent virions is a downstream consequence
of absent Vpu function, and that Vpu inhibits an activity that
prevents the release of completely assembled virions from the
PM (Figure 12). While the nature of this putative host-
restriction activity is unknown, its existence is the simplest
explanation for our ﬁndings and is completely consistent
with earlier studies on Vpu which showed that Vpu-defective
HIV-1 particles accumulate at the cell surface as well as in
intracellular vacuoles as mature virions [17,18]. One possi-
bility is that virions remain attached to cells via incorpo-
ration of cellular proteins with adhesive properties into the
viral membrane. That mature, Vpu-defective, virions can be
released from the cell surface by protease treatment,
particularly when endocytosis is inhibited, is entirely con-
sistent with this notion. Indeed, a variety of cell-surface
proteins are well known to be incorporated into the HIV-1
virion membrane [61]. This scenario has several conceptual
Figure 11. Absence of Vpu Results in Cell-Surface Entrapment of Mature
Virions
Subtilisin-induced release of mature, Vpu-defective HIV-1 particles from
HeLa cells. Hela cells were transfected with NL4.3 (A), NL4.3delVpu (B), or
NL4.3 (PTAP
 ) (C) proviral plasmids as indicated, in the presence of
CherryFP-Rab5a(S34N) or CherryFP-expression vectors. Cells and super-
natants were harvested 48 h post-transfection and analyzed directly (no
treatment), while cells in replicate wells were either treated with 1 mg/ml
subtilisin (þ subtilisin) or a buffer control (þ buffer) for 15 min at 37 8C.
Virions released by buffer or subtilisin and corresponding cell lysates
were harvested and analyzed by Western blotting with an anti p24CA
antibody as before.
DOI: 10.1371/journal.ppat.0020039.g011
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families. Many viruses that bind to sialic acid molecules for
cell entry require a neuraminidase enzyme to release nascent
virions from the cell surface [62]. Second, Vpu is known to
target two cell-surface receptors, CD4 [8] and MHC class I
[63], for destruction by proteosomes. Thus, Vpu-mediated
destruction of other speciﬁc cell-surface factors with adhesive
properties could conceivably enhance virion release.
Variations on this scenario are also possible. Because
endosomal localization of Vpu-defective HIV-1 Gag and MLV
exhibits a requirement for a functional L-domain, we
currently favor the interpretation that discontinuity of virion
and cell membrane is required for particle endocytosis.
However, it is also possible that whatever restriction factors
impose Vpu dependence and induce Gag endocytosis, they
are themselves indirectly recruited by L-domains. Indeed, L-
domain motifs are known to recruit ubiquitin ligases [54] and/
or class E VPS factors to sites of virus budding [51–53,64].
Since other class E VPS factors (for example Hrs [65] and AIP-
1/ALIX [66]) are known to also regulate endocytic trafﬁc, it is
entirely plausible that Vpu may prevent the L-domain–
dependent recruitment of endocytosis-inducing or virus
release–inhibiting factors to sites of virion assembly. In our
view, however, this model is less attractive, because it is more
difﬁcult (albeit not impossible) to reconcile with the
observation that the Vpu defect induces accumulation of
fully assembled mature virions at the cell surface [17,18]
(Figures 8 and 11) .
In conclusion, the results presented herein strongly suggest
that that Vpu prevents entrapment of nascent retroviral
particles at the cell surface and, as a consequence, subsequent
transport into early and late endosomal compartments. The
absence of a such a pathway in HOS cells, and the ﬁnding that
generalized inhibition of endocytosis ‘‘corrects’’ Gag local-
ization but does not enhance release, strongly suggests that
speciﬁc host-cell factors that are targeted by Vpu, but
otherwise prevent efﬁcient release of widely divergent
retroviruses from the PM, exist in some human cell types.
Clearly, the identiﬁcation of Vpu target factors that exhibit
such properties will be required to deﬁnitively show whether
or not such a model is correct.
Materials and Methods
Cells and plasmids. HeLa, HeLa-TZM, HOS, and Vero cells were
maintained in Dulbecco’s Modiﬁed Eagle Medium supplemented with
10% fetal calf serum and gentamycin. The expression vector pcDNA-
Vphu, expressing a codon-optimized HIV-1 Vpu protein from the
NL4.3 strain, was provided by K. Strebel (National Institutes of
Health, Bethesda, Maryland, United States) through the NIH AIDS
Research and Reference Reagent Program (Germantown, Maryland,
United States). A derivative of this plasmid in which the Vpu TM
domain was replaced by that of the human CD8 molecule was
constructed using an overlapping PCR-based approach. Similarly, a
Vpu-defective NL4.3-based proviral plasmid (NL4.3delVpu) was
constructed by introduction of a frame shift and replacement of
the initiating codon of Vpu with a BamH1 site using an overlapping
PCR-based approach. To express Vpu with C-terminal HA and YFP
tags, wild-type HIV-1 NL4.3 Vpu sequences were ampliﬁed by PCR
and inserted as an EcoR1-Xho1 fragment into the mammalian
expression plasmids pCR/HA and pCR/YFP that have previously been
described [67]. Plasmids expressing DN dynamin I (K44A) and DN
EPS-15 (dUIM) were kindly provided by M. Caron (Duke University,
Durham, North Carolina, United States) and S. Polo (FIRC Institute
for Molecular Oncology, Milan, Italy), respectively. Human Rab5a was
ampliﬁed from human placental cDNA and inserted as an EcoR1-
Xho1 fragment fused at its 59 end to a CherryFP cDNA (provided by
R. Tsien, University of California San Diego, San Diego, California,
United States) in a pCR3.1-based plasmid, to express a CherryFP-
Rab5a fusion protein. Mutants (S34N and Q79L) were derived using
overlapping PCR-based methods. Plasmids expressing wild-type and
mutant Gag-CFP fusion proteins, namely pCR/HIV-1Gag-CFP [60],
pCAGGS/MLVGag-CFP, pCAGGS/MLVGag(dPY)-CFP, and pCAGGS/
MLVGag(PTAPP)-CFP have been described previously [54,68]. A
derivative of pCR/HIV-1Gag-CFP lacking the bipartite L-domain in
p6 (PTAP and LRSLF were mutated to LTAL and LRSPS,
respectively) was generated using overlapping PCR methods.
Virus-release assays. HeLa, HOS, or Vero cells were seeded at 1 3
10
5 cells/well of a 24-well plate and were transfected with a total of 1
lg of DNA/well consisting of 800 ng of NL4.3, NL4.3delVpu, or MLV
Gag-Pol, together with 200 ng of Vpu, dynamin, EPS-15, or Rab5a-
expression vectors, using LipoFectamine 2000 (Invitrogen, Carlsbad,
California, United States). After 48 h, the cell supernatants were
harvested, ﬁltered (0.2 lm), and layered (500 ll) on to 400 ll of 20%
sucrose in PBS and centrifuged at 20,000 g for 90 min at 4 8C. Pelleted
virions were resuspended in SDS-PAGE loading buffer, as were
corresponding cell lysates. Virion and cell lysates were separated on
12% SDS-PAGE gels (Bio-Rad, Hercules, California, United States),
and proteins were transferred to nitrocellulose membranes which
were then probed with HIV-1 or MLV CA-speciﬁc monoclonal
antibodies (183-H12-5C or D175, respectively) and with the appro-
priate HRP-conjugated goat secondary antibodies.
In experiments where subtilisin-induced release of virions was
attempted, HeLa cells were transfected with NL4.3, NL4.3delVpu, or
NL4.3 (PTAP
 ) in the presence or absence of co-expressed
Rab5a(S34N). Viral supernatants were harvested as above, and
parallel wells were washed once with PBS and then either directly
harvested or, alternatively, incubated for 15 min at 37 8C in 100 llo f
Tris/HCl (pH 8.0), 150 mM NaCl, 5 mM CaCl2 with or without the
addition of subtilisin (1 mg/ml). The reaction was then stopped with
0.5 ml DMEM/FCS containing 5 mM PMSF. The supernatants were
ﬁltered (0.2 lm) and the virions pelleted through sucrose as described
above.
Infectious virus release was determined by inoculating HeLa-TZM
cells (CD4 and CCR5þ), which contain a lacZ reporter gene under the
control of an HIV-1 LTR. Sub-conﬂuent monolayers of HeLa-TZM
cells were infected for 4 h, washed, and b-galactosidase activity was
Figure 12. Model for the Role of Vpu in Retroviral Particle Release
Retroviral Gag molecules targeted to the PM (by unknown mechanisms)
require the recruitment of class E VPS factors to enable budding of
mature virions. At this point, nascent viral particles are subject to an
unknown, subtilisin-sensitive, host-cell type-specific restriction (depicted
as a question mark) that results in their retention at the cell surface.
Subsequently, endocytosis by a dynamin-, EPS-15-, and Rab5a-depend-
ent process result in intracellular accumulation in early/late endosomes,
where they may be simply sequestered, or perhaps destroyed, in
lysosomes. Vpu overcomes this restriction, leading to more efficient
release of virions from the cell surface. In contrast, inhibition of
endocytosis by DN mutants of dynamin, EPS-15, or Rab5a prevents the
accumulation of virions in endosomes, but does not enhance virion
release, suggesting Vpu inhibits a specific host-restriction activity, rather
than imposing a generalized inhibition on endocytosis.
DOI: 10.1371/journal.ppat.0020039.g012
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Vpu and Retrovirus Releasedetermined 48 h later using GalactoStar reagent (Tropix, Bedford,
Massachusetts, United States), as per the manufacturer’s instructions.
In experiments where MLV infectious titers were measured, an HIV-1
Tat–expressing, packageable MLV vector (LXSN/Tat) and VSV-G–
expression vectors were included in the particle-generating trans-
fection mixture.
Microscopy. Cells were seeded on 3.5-cm, glass-bottomed dishes
coated with poly-L-lysine (Mattek, http://www.mattek.com). The
following day, they were transfected with 1.5 lg of HIV-1 or MLV
Gag-CFP–expression vectors and 0.5 lgo fe m p t yp C R 3 . 1o r
expression vectors encoding Vpu, dynamin K44A, DN EPS-15, or
Rab5a, using polyethylenimine. Cells were ﬁxed at 16 to 18 h after
transfection, or at the time points indicated in the text, using 4%
paraformaldehyde for 10 min. Cells were then observed by
deconvolution microscopy using an Olympus IX70-based Deltavision
microscopy suite (Tokyo, Japan) and a 603 objective, and analyzed
using SoftWorx software (Applied Precision, Issaquah, Washington,
United States). CFP, YFP, and CherryFP fused proteins were excited
at 436, 500, and 575 nm respectively. Similar approaches were used to
determine the localization of Gag proteins expressed by the NL4.3
and NL4.3delVpu proviral plasmids in the presence or absence of co-
expressed CherryFP-Rab5a fusion proteins. However, in this case,
cells were permeabilized after ﬁxation with 1% TritonX-100 and then
stained by sequential incubations with an a-HIV-1 CA monoclonal
antibody (183-H12-5C) and an Alexa-Fluor-495–labeled a-murine IgG
conjugate. For electron microscopy studies, HeLa cells were trans-
fected with plasmids expressing HIV-1 Gag-Pol (pSYNGP) in the
presence or absence of plasmids expressing Vpu or CherryFP-
Rab5a(S34N). Cells were processed and examined by electron
microscopy as described previously [64,69].
Transferrin-uptake assays. HeLa cells were seeded on poly-L-
lysine–coated glass-bottomed plates (Mattek) and transfected the
following day with a total of 1 lg of 1:1 mixtures of pCR/GFP with
either pCR/HA, pcDNA-Vphu, or dynamin K44A-expression vectors
for 5 h using polyethylenimine. The cells were then washed and
serum-starved overnight. The cells were then incubated for 30 min on
ice in serum-free medium containing 5 lg/ml of Alexa-Fluor-568–
conjugated transferrin. The medium was replaced and the cells were
shifted to 37 8C for 15 min, then washed and ﬁxed in 4%
paraformaldehyde and observed by deconvolution microscopy as
described above.
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